title: [Validation of the FINDRISC (FINnish Diabetes RIsk SCore) for prediction of the risk of type 2 diabetes in a population of southern Spain. Pizarra Study].
abstract: OBJECTIVE
  The aim of this study was to validate the ability of the Finnish Diabetes Risk Score (FINDRISC) to predict the risk of DM2 in a population of south-eastern Spain (Pizarra Study).
  
  
  METHODS
  The Pizarra Study is a population-based prospective study developed in the town of Pizarra (Málaga). The first phase of the study was conducted in 1997-1998, including 1051 individuals aged 18-65 years randomly selected from the municipal census of the town. In 2003-2004 the subjects participating in the first study were reassessed. 824 individuals completed the second phase of the study (78.4%). All participants without known diabetes underwent an oral glucose tolerance test both at baseline and follow-up. We evaluated the ability of the FINDRISC to detect undiagnosed DM2 (first phase: cross-sectional study) and in predicting the incidence of DM2 (second phase: cohort study).
  
  
  RESULTS
  The test showed good results both to detect undiagnosed DM2 (ROC-AUC 0.74) and to predict incident DM2 (ROC-AUC 0.75). The best prediction of risk of incident DM2 was found in those subjects with fasting glucose >100mg/dl and a FINDRISC ≥9 (OR: 19.37; 95%IC: 8,86-42,34; P<.0001).
  
  
  CONCLUSIONS
  The results of our study show that FINDRISC can be a useful tool to detect subjects at high risk of diabetes in this population.
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Universitario Carlos Haya, Málaga, España. federico.soriguer.sspa@juntadeandalucia.es
authors.forename: Federico
authors.initials: F
authors.lastname: Soriguer
authors.forename: Sergio
authors.initials: S
authors.lastname: Valdés
authors.forename: María José
authors.initials: MJ
authors.lastname: Tapia
authors.forename: Isabel
authors.initials: I
authors.lastname: Esteva
authors.forename: María Soledad
authors.initials: MS
authors.lastname: Ruiz de Adana
authors.forename: María Cruz
authors.initials: MC
authors.lastname: Almaraz
authors.forename: Sonsoles
authors.initials: S
authors.lastname: Morcillo
authors.forename: Eduardo
authors.initials: E
authors.lastname: García Fuentes
authors.forename: Francisca
authors.initials: F
authors.lastname: Rodríguez
authors.forename: Gemma
authors.initials: G
authors.lastname: Rojo-Martinez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000886:Anthropometry; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology*; D050171:Dyslipidemias / Q000453:epidemiology; D005215:Fasting / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009765:Obesity / Q000453:epidemiology; D011446:Prospective Studies; D012494:Sampling Studies; D012720:Severity of Illness Index; D013030:Spain / Q000453:epidemiology; D055815:Young Adult
chemical_list: D001786:Blood Glucose